RmAb38E2

RmAb38E2 is a recombinant monoclonal antibody designed to selectively target oligomeric forms of alpha-synuclein (αSYN), which are considered the primary neurotoxic species in Parkinson's disease and other synucleinopathies. Developed by researchers at Uppsala University, the antibody exhibits high affinity for αSYN oligomers while showing minimal reactivity toward monomers or mature fibrils. In preclinical studies, the monospecific RmAb38E2 has demonstrated limited penetration of the blood-brain barrier; however, it serves as the foundational targeting component for bispecific constructs, such as RmAb38E2-scFv8D3. These bispecific versions utilize a transferrin receptor (TfR)-binding domain to facilitate active transport into the central nervous system via receptor-mediated transcytosis. The therapeutic goal of RmAb38E2 is to reduce the burden of toxic protein aggregates and modulate neuroinflammation, potentially slowing the progression of neurodegenerative disorders.

Other names

mAb38E2mAb-38E2mAb 38E2